Glioblastoma Vaccine Scores In Phase Ib Clinical Trial


A type of primary brain cancer named glioblastoma is one of the most aggressive ones with a prognosis of 11-15 Months with standard treatment. The current new experimental glioblastoma vaccine developed by Jefferson and Imvax is in the phase 1b clinical trial and has shown a reduction in tumor recurrence, increase in patients’ tolerance level,  and prolonged patient survival. The researchers have tested the novel cancer vaccine (IGV-001) on the volunteers with glioblastoma multiforme and the results have been explicable. The vaccine helped increase overall survival and also enhance progression-free survival opportunities in comparison to the standard care.

The clinical trials on the vaccine are still ongoing before it is tested on humans. The results so far have been encouraging. The vaccine consists of antisense oligodeoxynucleotide (AS-ODN) that act against IGF-R1, tumor growth and metastasis enhancer, and additional AS-ODN which is implanted into the skin of the patient’s abdomen. The combination of the IGF-1R antisense and irradiation have shown to affect the tumor cells that release antigens connected with the immunomodulatory AS-ODN, which then activates the immune system to fight brain tumor cells. The treatment of glioblastoma using conventional radiotherapy has proved difficult; thus, using antisense molecules is a good option instead.

The two main measure rendering cancer treatments successful include progression-free survival and overall survival, which has proved positive in case of this new Imvax glioblastoma vaccine. The side effects related to the vaccine has proved nil. The basic idea is to brainstorm a potential solution for challenging the limitations of medicines. Researchers from Marshall University have found a strong connection between its consumption on a daily basis and growth and survival restrains in breast cancers.

Leave A Reply

Your email address will not be published.